Abstract. BACKGROUND: Skin melanocytes can give rise to benign and malignant neoplasms. Discrimination of an early melanoma from an unusual/atypical benign nevus can represent a significant challenge. However, previous studies have shown that in contrast to benign nevi, melanoma demonstrates pervasive chromosomal aberrations. OBJECTIVE: This substantial difference between melanoma and benign nevi can be exploited to discriminate between melanoma and benign nevi. METHODS: Array-comparative genomic hybridization (aCGH) is an approach that can be used on DNA extracted from formalin-fixed paraffin-embedded (FFPE) tissues to assess the entire genome for the presence of changes in DNA copy number. In this study, high resolution, genome-wide single-nucleotide polymorphism (SNP) arrays were utilized to perform comprehensive and detailed analyses of recurrent copy number aberrations in 41 melanoma samples in comparison with 21 benign nevi. RESULTS: We found statistically significant copy number gains and losses within melanoma samples. Some of the identified aberrations are previously implicated in melanoma. Moreover, novel regions of copy number alterations were identified, revealing new candidate genes potentially involved in melanoma pathogenesis. CONCLUSIONS: Taken together, these findings can help improve melanoma diagnosis and introduce novel melanoma therapeutic targets.
Background 1
In the United States, skin cancer is the most common 2 of all cancers [1] . Most cases of skin cancer are non-3 melanoma skin cancer. In fact, melanoma accounts for 4 less than 2% of skin cancer cases [1] . Melanoma is 5 a cancer that arises from the malignant transforma-6 tion of epidermal melanocytes, pigment-synthesizing 7 cells of the skin. When melanoma escapes early de-8 tection, it becomes one of the most aggressive and 9 highly lethal forms of cancer. Although it accounts 10 for the minority of skin cancers, a large majority 11 (75%) of skin cancer related-deaths are accounted for 12 by melanoma [1, 2] . The incidence and mortality of 13 melanoma has increased dramatically in the last few 14 decades [3] . The American Cancer Society estimates 15 that about 73,870 people in United States will be diag-16 nosed with melanoma in 2015 and about 9,940 people 17 are expected to die from the disease. Importantly, the 18 5-year survival rate of melanoma depends on the stage 19 of the disease when it is diagnosed. It can be as high 20 as 98% when the melanoma is detected early before 21 it spreads to the lymph nodes or other organs. When 22 melanoma reaches the lymph nodes, the 5-year sur-23 vival rate drops to 62%, and to 15% when melanoma 24 spread to other organs [2] . Different factors are re- 25 ISSN 1574-0153/16/$35.00 c 2016 -IOS Press and the authors. All rights reserved More recently, cytogenetic analyses have been devel- 77 oped and become popular methods in the area of dis-78 tinguishing melanoma from benign nevi. For instance, 79 using fluorescence in situ hybridization (FISH) as-80 says as an adjunctive test in the diagnosis of ambigu-81 ous melanocytic tumors have been increasingly uti-82 lized in dermatopathology laboratories. Several stud-83 ies have shown the potential of the FISH assay as a 84 successful discriminatory test that can distinguish be-85 tween problematic melanocytic lesions [7, [18] [19] [20] [21] . Cur-86 rently, the most commonly used FISH assay employs 87 a 4-probe panel targeting 4 loci (RREB1, MYB, cen-88 tromere 6, and CCND1) on 2 different chromosomes. 89 The 4-probes FISH has shown a sensitivity and speci-90 ficity of 86.7% and 95.4% respectively [18] . Recent 91 study has shown an improvement of the FISH assay by 92 incorporating new probes that target 4 different chro-93 mosomes (CDKN2A on 9p21, RREB1 on 6p25, MYC 94 on 8q24 and CCND1 on 11q13) with increased sensi- 95 tivity and specificity to 94% and 98% respectively [7] . 96 Although the FISH assay was introduced as a di-97 agnostic tool in the field of differential diagnosis of 98 melanoma fairly recently, the principle of developing 99 this assay was based on findings that existed over a 100 decade ago. After the emersion of comparative ge-101 nomic hybridization as a novel technique that can 102 screen the entire genome for copy number changes 103 in one experiments in 1992 [22] , several studies (by 104 Bastian and others) have revealed that the majority of 105 melanomas differ from benign nevi in their genetic 106 makeup. These studies demonstrated gain or loss of 107 specific chromosomal segments and showed that the 108 majority of melanomas harbor recurrent chromoso-109 mal copy number aberrations. With some exceptions 110 such as in Spitz nevi, these chromosomal rearrange-111 ments are rarely detected in melanocytic nevi [23- 112 26] . Frequent genomic alterations known to occur in 113 melanoma include gains at 1q, 6p, 7p, 7q, 8q, 17q and 114 20q in conjunction with deletions at 6q, 8p, 9p, 9q, 115 10p, 10q, 11q and 21q [23] [24] [25] . These fundamental dif-116 ferences in the pattern of genetic alterations between 117 melanomas and benign nevi established the idea that 118 copy number variations can be diagnostically valuable 119 for histopathologically ambiguous melanocytic neo-120 plasms. Therefore, developing diagnostic assays tar-121 geting these genetic differences, such as FISH as-122 says, would help improve the differential diagnosis and 123 prognosis of melanoma.
124
Utilizing CGH as a research tool has been decid-125 edly a huge advancement in the cancer research field. 126 As previously mentioned, the use of CGH has en-127 Therefore, these advances in array CGH technology 157 have provided great opportunities to detect novel and 158 previously unrecognized key driver genes that can help 159 improve melanoma prognosis, diagnosis, and even aid 160 development of targeted therapies.
161
Here, we report our investigation for chromosomal 162 aberrations that can help in the identification of ge- 
Specimen collection and preparation

180
Following IRB review, total of 62 specimens (41 181 melanoma plus 21 benign nevi) were selected from a 182 large archive of FFPE skin biopsies collected at a na-183 tional dermatopathology laboratory (Dermatopathol- 184 ogy Laboratory of Central States, DLCS, Dayton, OH). 185 Patients ranged in age from 14 to 90 years (Table 1) . 186 The cohort of biopsy specimens used in this study was 187 collected between 2001 and 2013, making their age 188 range between 2 and 14 years. Specimens were stored 189 in a temperature-controlled environment. Melanomas 190 were all between stages II and V, and were verified by a 191 qualified dermatopathologist. Upon review, melanoma 192 specimens with less than 60% tumor tissue (such as 193 specimens with a brisk lymphocytic infiltrate) were ex-194 cluded from study.
195
De-identified retrospective clinical data were ob-196 tained from clinical databases and patient health 197 records at DLCS. For all experiments, 10 μm thick sec-198 tions were taken for each sample from paraffin blocks 199 by using a microtome with disposable blades. Care was 200 taken to avoid contamination between the specimens 201 by wearing gloves when handling the blocks, cleaning 202 the microtome after cutting a block, and using fresh 203 blades for each specimen. The sections were placed 204 in a warm water bath and then mounted on slides to 205 be air dried. The first and last slides from each block 206 were stained with H&E to verify that the region of 207 interest (consisting of cellular material) had not been 208 exhausted. Tissue was then scraped from slides us-209 ing sterile scalpel blades into 1.5 mL microcentrifuge 210 tubes or Screw-Cap microTUBES (Covaris, Woburn, 211 MA, USA) for DNA extraction. The number of sec-212 tions taken per sample varies between methods, as de-213 scribed below. 
DNA Isolation from FFPE tissues
215
DNA isolation was carried out using column-based 216 methods. Qiagen QIAamp DNA FFPE tissue kit (Qia-217 gen, Valencia, CA, USA) or adaptive focused acoustics 218 (AFA)-based extraction using the Covaris truXTRAC 219 FFPE DNA kit (Covaris).
220
For the Qiagen method, 24 sections of 10 μm thick-221 ness FFPE tissues were used as suggested by the man-222 ufacturer with some modifications as follows. Deparaf-223 finization of FFPE tissues was performed by incubat- 224 ing twice in 1 mL xylene, then in a descending con-225 
Microarrays
298
DNA copy number analysis was performed by hy-299 bridizing the extracted and qualified gDNA to Affy-300 metrix SNP6.0 microarrays (Affymetrix, Santa Clara, 301 CA, USA). All samples passed RAPD-PCR quality 302 control. 0.5 μg of genomic DNA was processed using 303 the SNP 6.0 protocol and microarrays by Affymetrix 304 with some modifications to the standard protocol. The 305 input amount of DNA was increased from 250 ng per 306 restriction enzyme (Nsp1 and Sty1) to 500 ng each. 307 The number of PCR reactions was doubled from the 308 suggested three for Sty1 and four for Nsp1 to six for 309 Sty1 and eight for Nsp1. It is important to note that the 310 number of reactions was increased; the number of cy-311 cles in each reaction remained the same. The additional 312 PCR reactions were combined as in the standard proto-313 col. PCR cleanup was performed using isopropanol ex-314 traction (refer to Affymetrix User Bulletin 2: Improve-315 ments to step 7 of the SNP Assay 6.0, PCR cleanup us-316 ing an isopropanol precipitation method, P/N 702968 317 Rev. 1). Hybridization and scanning of the arrays fol-318 lowed the manufacturer's protocol to generate SNP6.0 319 CEL files. Ras/MAPK, Jun N-terminal kinase "JNK" and PLC-441 dependent pathways [58, 62] .
442
In melanoma, a study on human melanoma cell lines 443 has showed a correlation between the expression of 444 RET and melanomagenesis. Also, the study showed 445 that inhibition of RET signaling suppressed all prolif-446 eration and invasion in melanoma [62] . Another study 447 reported the involvement of RET in melanoma devel-448 opment in RET-mice and human melanoma cells [63] .
449
These two studies besides the focal region of amplifi- characterized [65] . In our study, this peak at 6p24.3 464 represents a partial gain of 6p (22.74 Mb). Interest-465 ingly, several important genes in melanoma were iden-466 tified in this peak. NEDD9, one of the main melanoma 467 metastasis genes [35] , RREB1, one of the FISH assay 468 targets that is used to distinguish between melanoma 469 and benign nevi [7] , and DEK, an oncogene that was 470 reported to have a dual and selective roles in prolifer-471 ation and apoptotic resistance in melanoma [65] . An-472 other important gene in this region is E2F3 gene, an 473 oncogene that has an important role in tumorigenesis in 474 bladder cancer [66] . Therefore, against the large back-475 ground of 6p gain that is common in melanoma, the 476 partial gain of this part of chromosome 6p in our analy-477 sis, with known genes in melanoma located in this part, 478 minimizes the broad gain of 6p to a smaller region that 479 is highly associated with melanoma. Gain of 8q is another hallmark in melanoma that 496 was reported in many different studies [4, 6, 25, 26, 72] . 497 In our findings, the peak on chromosome 8 represent 498 high amplification of a part of the long arm of chro-499 mosome 8, which is 8q24. A study has suggested that 500 targeting this region 8q24 by FISH assays could be a 501 useful prognostic marker in melanoma cancers [73] . A 502 later study that sought to improve the sensitivity and 503 specificity of FISH assay for discriminating melanoma 504 from nevi has confirmed and included the 8q24 re-505 gion as one of four FISH targets with high discrimi-506 natory power to differentiate between melanoma and 507 benign nevi [7] . The most prominent gene in this re-508 gion is MYC, a proto-oncogene that encodes a nu-509 clear phosphoprotein transcription factor that plays a 510 role in different cellular processes, such as prolifer-511 ation, cell cycle progression, metabolism, differentia-512 tion and apoptosis [74] [95] , ovary cancer [96] , 588 and more common in the head and neck squamous cell 589 carcinoma (HNSCC) and correlates with poor prog-590 nosis [97, 98] . In melanoma, a recent study of Tang 591 et al. has reported that CSMD1 functions as a tumor 592 suppressor gene in melanoma cells. They found that 593 the level of CSMD1 mRNA and protein in melanoma 594 cells was lower than in normal skin cancer. Also, they 595 showed that CSMD1 expression decreased prolifera-596 tion and migration, and increased apoptosis and G1 ar-597 rest in A375 melanoma cells in vitro. Furthermore, the 598 survival rate of mice with tumors expression CSMD1 599 was significantly higher than mice with tumors that 600 did not express CSMD1. Moreover, the study showed 601 that CSMD1 exhibits antitumor activity through ac-602 tivation of Smad pathway [99] . That study and our 603 study provide CSMD1 as a candidate biomarker gene 604 in melanoma. [112] . Different studies and biolog-694 ical evidences support the existence of melanoma tu-695 mor suppressor genes on chromosome 11q, and dele-696 tion of this chromosome in melanoma has been re-697 ported to be associated with advanced tumor stage, 698 younger age at presentation, poorer prognosis, and 699 metastasis to the brain [109] . In our study, a focal dele-700 tion of ∼94 kb region was defined in this chromoso-701 mal arm. This narrow region contains the ovarian tu-702 mor domain-containing Ub aldehyde-binding protein 703 1 (OTUB1). OTUB1 is expected to play broad func-704 tions in cells [113] 891 reported that LPLUNC1 inhibist NPC cell proliferation 892 through inactivation Stat3. Induction of LPLUNC1 893 overexpression inhibited NPC cell proliferation, in-894 duced NPC cell arrest, promoted NPC cell apoptosis 895 even after IL-6 stimulation, and inhibited the growth 896 of implanted NPC tumors in vivo, which were associ-897 ated with decreasing cyclin D1 and Bcl-2 expression 898 and the Janus kinase 2 (JAK2)/Stat3 activation, but en-899 hancing Bax and p21 expression [147] . 
6q14.1 901
The gene SH3BGRL2 is a paralog to SH3BGRL. 902 While the latter has been shown to contribute to Rel-903 mediated transformation when inactivated [148] , so 904 such role has yet been identified in the former. Interestingly, 11p has been reported with reduced 992 copy number in melanoma [25] . Loss of 21q22.3 has been shown to be associated 995 with melanoma [179] . Within this large deletion, the 996 transient receptor potential channel gene TRPM2 has 997 been shown to increase the susceptibility of melanoma 998 to apoptosis and necrosis [180] . An antisense tran-999 script of TRPM2 is up-regulated in melanoma (ibid). 1000 Intriguingly, the related gene TRPM1 (melastatin, at 1001 15q13.3) has been known to be downregulated in 1002 highly metastatic melanoma [181] . 21q22.3 deletion is 1003 also observed in prostate cancer [182] . File: cbm-1-cbm600.tex; BOKCTP/wyn p. 13 This deletion includes the last exon of PPM1B.
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1030
PPM1B is thought to act as a phosphatase toward
1031
IKKβ, thereby attenuating the activity of NF-κB [187] .
1032
This locus as a whole is involved in 2p21 Deletion Syn-1033 drome (OMIM #606407), which is not known to con-1034 tribute to an elevated prevalence of any cancers. bility gene [188, 189] and it is deletion or loss of 1044 expression in melanoma is well-known [188] [189] [190] [191] .
1045
As was mentioned above, other important genes are 1046 also located in this region. CDKN2B is one of the 1047 genes located at 9p21 and has been shown to be 1048 deleted in melanoma [6, 192] and other cancers such
1049
as cutaneous T-cell lymphoma [193] . Interestingly, This deletion has been observed previously in sev-1114 eral cancers, but not to our knowledge in melanoma. 1115 Notably, 13q34 is lost in 45% of cutaneous anaplas-1116 tic large cell lymphoma [221] , 67% of chronic lym-1117 phocytic leukemias [222] , and 8% of Burkitt lym-1118 phomas [223] . It has also been noted missing in some 1119 cervical squamous cell carcinomas [224] [225] [226] , breast 1120 cancer cases showing centrosome abnormalities [227] , 1121 one case of chronic lymphocytic leukemia [228] , 1122 esophageal squamous cell carcinoma [229] , bladder 1123 Table 2 Significant copy number variation. Regions of variation are ordered by q-value (an upper bound on the expected fraction of false positives). Location of each CNV is given as genomic location and coordinates. The number of known genes within each region was determined from the hg19 assembly of the human genome. Genes of interest (those known to play a role in cancer, or specifically in melanoma) are featured, and references to the relevant studies are given in the Results section 1188 has shown an improvement of the FISH assay by in-1189 corporating new probes that target 4 different chromo-1190 somes (CDKN2A on 9p21, RREB1 on 6p25, MYC on 1191 8q24 and CCND1 on 11q13) with increased sensitiv-1192 ity and specificity to 94% and 98% respectively [7] . 1193 Due to the technical limitations of FISH, the justifica-1194 tion for adding a locus to the analysis must overcome 1195 the consequences of removing another. CGH or aCGH 1196 itself, as here, could be developed as diagnostic tools 1197 for melanoma and indeed this is described in the lit-1198 erature [21] . A third potential approach is the addition 1199 of CNV observed here to qPCR-based assays like the 1200 duplex ratio tests described by Moore et al. [240] . This 1201 has the advantage of being amenable to FFPE speci-1202 mens and being imminently expandable to incorporate 1203 new loci.
1204
Moreover, GISTIC detected key genomic regions 1205 whose genes seem to play important roles in melanoma 1206 pathogenesis. Some of these novel identified genes (es-1207 pecially in significant region of amplifications) are po-1208 tential candidates for molecular targeted therapies. In 1209 fact, proposed therapies have been introduced target-1210 ing some of the novel genes identified in our analysis, 1211 such as targeting the RET gene with small receptor ty-1212 rosine kinase inhibitors in thyroid cancer (specifically 1213 for identified activating mutations in RET) and other 1214 cancers [241] [242] [243] . Another gene that is being targeted 1215 for cancer therapy is ERG transcription factor, the gene 1216 with the most significant copy number gain in our anal-1217 ysis. Several studies have reported their attempts in de-1218 veloping drugs that target the ERG transcription fac-1219 tor, mostly in prostate cancer [244, 245] . Further vali-1220 dation of the results described here would suggest the 1221 expansion of such trials to include melanoma. ton, OH) for providing specimens and expert der-1226 matopathological assistance for these studies. This 
